Tumorigenic potential of circulating prostate tumor cells

L. Filipe Carvalho, Brian W. Simons, Emmanuel Antonarakis, Zeshaan Rasheed, Nora Douglas, Daniela Villegas, William Matsui, David M. Berman

Research output: Contribution to journalArticle

Abstract

Circulating tumor cells (CTCs) have received intense scientific scrutiny because they travel in the bloodstream and are therefore well situated to mediate hematogenous metastasis. However, the potential of CTCs to actually form new tumors has not been tested. Popular methods of isolating CTCs are biased towards larger, more differentiated, non-viable cells, creating a barrier to testing their tumor forming potential. Without relying on cell size or the expression of differentiation markers, our objective was to isolate viable prostate CTCs from mice and humans and assay their ability to initiate new tumors. Therefore, blood was collected from transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and from human patients with metastatic castration-resistant prostate cancer (PCa). Gradient density centrifugation or red cell lysis was used to remove erythrocytes, and then leukocytes were depleted by magnetic separation using CD45 immunoaffinity beads. CTCs fractions from TRAMP mice and PCa patients were verified by immunocytochemical staining for cytokeratin 8 and EpCAM, and inoculated into immunodeficient mice. TRAMP tumor growth was monitored by palpation. Human tumor growth formation was monitored up to 8 months by ultrasensitive PSA assays performed on mouse serum. We found viable tumor cells present in the bloodstream that were successfully isolated from mice without relying on cell surface markers. Two out of nine immunodeficient mice inoculated with TRAMP CTCs developed massive liver metastases. CTCs were identified in blood from PCa patients but did not form tumors. In conclusion, viable CTCs can be isolated without relying on epithelial surface markers or size fractionation. TRAMP CTCs were tumorigenic, so CTCs isolated in this way contain viable tumor-initiating cells. Only two of nine hosts grew TRAMP tumors and none of the human CTCs formed tumors, which suggests thatmost CTCs have relatively low tumor-forming potential. Future studies should identify and target the highly tumorigenic cells.

Original languageEnglish (US)
Pages (from-to)413-421
Number of pages9
JournalOncotarget
Volume4
Issue number3
StatePublished - Mar 2013

Fingerprint

Circulating Neoplastic Cells
Prostate
Transgenic Mice
Adenocarcinoma
Neoplasms
Prostatic Neoplasms
Keratin-8
Neoplasm Metastasis
Density Gradient Centrifugation
Neoplastic Stem Cells
Palpation
Castration
Differentiation Antigens
Growth
Cell Size
Leukocytes

Keywords

  • Circulating tumor cells
  • EpCAM
  • Prostate cancer
  • Prostate-specific antigen
  • TRAMP mouse

ASJC Scopus subject areas

  • Oncology

Cite this

Carvalho, L. F., Simons, B. W., Antonarakis, E., Rasheed, Z., Douglas, N., Villegas, D., ... Berman, D. M. (2013). Tumorigenic potential of circulating prostate tumor cells. Oncotarget, 4(3), 413-421.

Tumorigenic potential of circulating prostate tumor cells. / Carvalho, L. Filipe; Simons, Brian W.; Antonarakis, Emmanuel; Rasheed, Zeshaan; Douglas, Nora; Villegas, Daniela; Matsui, William; Berman, David M.

In: Oncotarget, Vol. 4, No. 3, 03.2013, p. 413-421.

Research output: Contribution to journalArticle

Carvalho, LF, Simons, BW, Antonarakis, E, Rasheed, Z, Douglas, N, Villegas, D, Matsui, W & Berman, DM 2013, 'Tumorigenic potential of circulating prostate tumor cells', Oncotarget, vol. 4, no. 3, pp. 413-421.
Carvalho LF, Simons BW, Antonarakis E, Rasheed Z, Douglas N, Villegas D et al. Tumorigenic potential of circulating prostate tumor cells. Oncotarget. 2013 Mar;4(3):413-421.
Carvalho, L. Filipe ; Simons, Brian W. ; Antonarakis, Emmanuel ; Rasheed, Zeshaan ; Douglas, Nora ; Villegas, Daniela ; Matsui, William ; Berman, David M. / Tumorigenic potential of circulating prostate tumor cells. In: Oncotarget. 2013 ; Vol. 4, No. 3. pp. 413-421.
@article{2a1f84078ea8444ea3c9a3c6f560385a,
title = "Tumorigenic potential of circulating prostate tumor cells",
abstract = "Circulating tumor cells (CTCs) have received intense scientific scrutiny because they travel in the bloodstream and are therefore well situated to mediate hematogenous metastasis. However, the potential of CTCs to actually form new tumors has not been tested. Popular methods of isolating CTCs are biased towards larger, more differentiated, non-viable cells, creating a barrier to testing their tumor forming potential. Without relying on cell size or the expression of differentiation markers, our objective was to isolate viable prostate CTCs from mice and humans and assay their ability to initiate new tumors. Therefore, blood was collected from transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and from human patients with metastatic castration-resistant prostate cancer (PCa). Gradient density centrifugation or red cell lysis was used to remove erythrocytes, and then leukocytes were depleted by magnetic separation using CD45 immunoaffinity beads. CTCs fractions from TRAMP mice and PCa patients were verified by immunocytochemical staining for cytokeratin 8 and EpCAM, and inoculated into immunodeficient mice. TRAMP tumor growth was monitored by palpation. Human tumor growth formation was monitored up to 8 months by ultrasensitive PSA assays performed on mouse serum. We found viable tumor cells present in the bloodstream that were successfully isolated from mice without relying on cell surface markers. Two out of nine immunodeficient mice inoculated with TRAMP CTCs developed massive liver metastases. CTCs were identified in blood from PCa patients but did not form tumors. In conclusion, viable CTCs can be isolated without relying on epithelial surface markers or size fractionation. TRAMP CTCs were tumorigenic, so CTCs isolated in this way contain viable tumor-initiating cells. Only two of nine hosts grew TRAMP tumors and none of the human CTCs formed tumors, which suggests thatmost CTCs have relatively low tumor-forming potential. Future studies should identify and target the highly tumorigenic cells.",
keywords = "Circulating tumor cells, EpCAM, Prostate cancer, Prostate-specific antigen, TRAMP mouse",
author = "Carvalho, {L. Filipe} and Simons, {Brian W.} and Emmanuel Antonarakis and Zeshaan Rasheed and Nora Douglas and Daniela Villegas and William Matsui and Berman, {David M.}",
year = "2013",
month = "3",
language = "English (US)",
volume = "4",
pages = "413--421",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "3",

}

TY - JOUR

T1 - Tumorigenic potential of circulating prostate tumor cells

AU - Carvalho, L. Filipe

AU - Simons, Brian W.

AU - Antonarakis, Emmanuel

AU - Rasheed, Zeshaan

AU - Douglas, Nora

AU - Villegas, Daniela

AU - Matsui, William

AU - Berman, David M.

PY - 2013/3

Y1 - 2013/3

N2 - Circulating tumor cells (CTCs) have received intense scientific scrutiny because they travel in the bloodstream and are therefore well situated to mediate hematogenous metastasis. However, the potential of CTCs to actually form new tumors has not been tested. Popular methods of isolating CTCs are biased towards larger, more differentiated, non-viable cells, creating a barrier to testing their tumor forming potential. Without relying on cell size or the expression of differentiation markers, our objective was to isolate viable prostate CTCs from mice and humans and assay their ability to initiate new tumors. Therefore, blood was collected from transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and from human patients with metastatic castration-resistant prostate cancer (PCa). Gradient density centrifugation or red cell lysis was used to remove erythrocytes, and then leukocytes were depleted by magnetic separation using CD45 immunoaffinity beads. CTCs fractions from TRAMP mice and PCa patients were verified by immunocytochemical staining for cytokeratin 8 and EpCAM, and inoculated into immunodeficient mice. TRAMP tumor growth was monitored by palpation. Human tumor growth formation was monitored up to 8 months by ultrasensitive PSA assays performed on mouse serum. We found viable tumor cells present in the bloodstream that were successfully isolated from mice without relying on cell surface markers. Two out of nine immunodeficient mice inoculated with TRAMP CTCs developed massive liver metastases. CTCs were identified in blood from PCa patients but did not form tumors. In conclusion, viable CTCs can be isolated without relying on epithelial surface markers or size fractionation. TRAMP CTCs were tumorigenic, so CTCs isolated in this way contain viable tumor-initiating cells. Only two of nine hosts grew TRAMP tumors and none of the human CTCs formed tumors, which suggests thatmost CTCs have relatively low tumor-forming potential. Future studies should identify and target the highly tumorigenic cells.

AB - Circulating tumor cells (CTCs) have received intense scientific scrutiny because they travel in the bloodstream and are therefore well situated to mediate hematogenous metastasis. However, the potential of CTCs to actually form new tumors has not been tested. Popular methods of isolating CTCs are biased towards larger, more differentiated, non-viable cells, creating a barrier to testing their tumor forming potential. Without relying on cell size or the expression of differentiation markers, our objective was to isolate viable prostate CTCs from mice and humans and assay their ability to initiate new tumors. Therefore, blood was collected from transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and from human patients with metastatic castration-resistant prostate cancer (PCa). Gradient density centrifugation or red cell lysis was used to remove erythrocytes, and then leukocytes were depleted by magnetic separation using CD45 immunoaffinity beads. CTCs fractions from TRAMP mice and PCa patients were verified by immunocytochemical staining for cytokeratin 8 and EpCAM, and inoculated into immunodeficient mice. TRAMP tumor growth was monitored by palpation. Human tumor growth formation was monitored up to 8 months by ultrasensitive PSA assays performed on mouse serum. We found viable tumor cells present in the bloodstream that were successfully isolated from mice without relying on cell surface markers. Two out of nine immunodeficient mice inoculated with TRAMP CTCs developed massive liver metastases. CTCs were identified in blood from PCa patients but did not form tumors. In conclusion, viable CTCs can be isolated without relying on epithelial surface markers or size fractionation. TRAMP CTCs were tumorigenic, so CTCs isolated in this way contain viable tumor-initiating cells. Only two of nine hosts grew TRAMP tumors and none of the human CTCs formed tumors, which suggests thatmost CTCs have relatively low tumor-forming potential. Future studies should identify and target the highly tumorigenic cells.

KW - Circulating tumor cells

KW - EpCAM

KW - Prostate cancer

KW - Prostate-specific antigen

KW - TRAMP mouse

UR - http://www.scopus.com/inward/record.url?scp=84879007968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879007968&partnerID=8YFLogxK

M3 - Article

C2 - 23530114

AN - SCOPUS:84879007968

VL - 4

SP - 413

EP - 421

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 3

ER -